Pharmaceuticals and Biotechnology

  • “I have worked closely with Stradling on several financing deals over the past 7 years. I have found them to be knowledgeable, fair, responsive and thoughtful. They have been able and willing to address complex problems and to propose straightforward and workable answers. The attorneys at SYCR have successfully negotiated several difficult transactions, including successfully handling protracted negotiations among founders, senior executives, universities and several venture capital funds. The SYCR advisory role with respect to the technology and financial terms were instrumental in the success of the deals.”

    Dr. Russell Lebovitz,
    CEO, DX Biosciences